Paula M Cannon
Overview
Explore the profile of Paula M Cannon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
55
Citations
2140
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
DiGiusto D, Cannon P, Holmes M, Li L, Rao A, Wang J, et al.
Mol Ther Methods Clin Dev
. 2016 Dec;
3:16067.
PMID: 27900346
Gene therapy for HIV-1 infection is a promising alternative to lifelong combination antiviral drug treatment. Chemokine receptor 5 (CCR5) is the coreceptor required for R5-tropic HIV-1 infection of human cells....
22.
Wang C, Cannon P
AIDS Patient Care STDS
. 2016 Nov;
30(12):539-544.
PMID: 27854119
Despite significant advances in HIV drug treatment regimens, which grant near-normal life expectancies to infected individuals who have good virological control, HIV infection itself remains incurable. In recent years, novel...
23.
Lederman M, Cannon P, Currier J, June C, Kiem H, Kuritzkes D, et al.
Pathog Immun
. 2016 Sep;
1(1):154-164.
PMID: 27668293
With the advent and stunning success of combination antiretroviral therapy (ART) to prolong and improve quality of life for persons with HIV infection, HIV research has been afforded the opportunity...
24.
Woodham A, Skeate J, Sanna A, Taylor J, Da Silva D, Cannon P, et al.
AIDS Patient Care STDS
. 2016 Jul;
30(7):291-306.
PMID: 27410493
In the last three decades, extensive research on human immunodeficiency virus (HIV) has highlighted its capability to exploit a variety of strategies to enter and infect immune cells. Although CD4(+)...
25.
Wang C, Cannon P
Blood
. 2016 Apr;
127(21):2546-52.
PMID: 27053530
HIV/AIDS has long been at the forefront of the development of gene- and cell-based therapies. Although conventional gene therapy approaches typically involve the addition of anti-HIV genes to cells using...
26.
Wang J, Exline C, DeClercq J, Llewellyn G, Hayward S, Li P, et al.
Nat Biotechnol
. 2015 Nov;
33(12):1256-1263.
PMID: 26551060
Genome editing with targeted nucleases and DNA donor templates homologous to the break site has proven challenging in human hematopoietic stem and progenitor cells (HSPCs), and particularly in the most...
27.
Exline C, Yang S, Haworth K, Rengarajan S, Lopez L, Droniou M, et al.
Retrovirology
. 2015 Aug;
12:67.
PMID: 26248668
Background: The interferon-inducible factor BST-2/tetherin blocks the release of nascent virions from the surface of infected cells for certain enveloped virus families. The primate lentiviruses have evolved several counteracting mechanisms...
28.
Rathbun J, Droniou M, Damoiseaux R, Haworth K, Henley J, Exline C, et al.
J Virol
. 2015 Jun;
89(16):8428-43.
PMID: 26041296
Unlabelled: Certain members of the Arenaviridae family are category A agents capable of causing severe hemorrhagic fevers in humans. Specific antiviral treatments do not exist, and the only commonly used...
29.
Corrigan-Curay J, OReilly M, Kohn D, Cannon P, Bao G, Bushman F, et al.
Mol Ther
. 2015 May;
23(5):796-806.
PMID: 25943494
No abstract available.
30.
Gardner M, Kattenhorn L, Kondur H, von Schaewen M, Dorfman T, Chiang J, et al.
Nature
. 2015 Feb;
519(7541):87-91.
PMID: 25707797
Long-term in vivo expression of a broad and potent entry inhibitor could circumvent the need for a conventional vaccine for HIV-1. Adeno-associated virus (AAV) vectors can stably express HIV-1 broadly...